News

Indwelling devices and previous antibiotic exposure increased the risk for these infections.

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.

Ohio is now dealing with an outbreak, and the Centers for Disease Control and Prevention (CDC) reports nearly 500 total cases in the US.

Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.

Clinical-stage company, BiomX, said its therapy, BX211, was found to be safe and efficacious for this infection that was associated with Staphylococcus aureus.

Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.

The organization's reports discuss the small number of newly approved treatments, the limited, late-stage antifungal pipeline, and challenges around diagnostics for this class of infections.

Ashraf S Ibrahim, PhD, details over 20 years of research on a spore coating protein and the development of VX-01 to block fungal tissue invasion.

Ashraf S Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.

New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.

Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president, discusses the potential implications these layoffs will have on clinicians and overall public health.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

The Visby Medical Women’s Sexual Health Test can screen for chlamydia, gonorrhea, and trichomoniasis.

This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.

Pamela Kushner, MD, offers insights on the newly approved antibiotic including its novel mechanism of action, the new criteria incorporated into the phase 3 studies, and what it means for her to have this treatment available.

The department is set to lay off 10,000 full-time employees, and with combined efforts, expects the reduction to be a total downsizing of 20,000 employees.

In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.

The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.

Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.

David Wohl, MD, explains the health risks of visceral fat and the role of treatments like Tesamorelin F8 in managing the condition.

David Wohl, MD, discusses the complexities of diagnosing and the importance of managing ectopic fat in HIV patients.

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.

This is the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in nearly 30 years.

Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.

In the second installment of our COVID-19 pandemic series, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), discusses the paradox that has arisen from the COVID-19 vaccines that in spite of their development in record time, what remains is a deeper mistrust in immunizations overall.

Studies highlight the role of home visits, chest radiography, and sputum monitoring in TB prevention and treatment outcomes.

This method represents a significant advancement in case management for this population. In our latest From Pathogen to Infectious Disease Diagnosis Podcast, Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, provides insights on its capabilities and how it can potentially aid clinicians in reducing antimicrobial resistance.

A 26% rise in childhood tuberculosis cases underscores the need for strengthened global TB control efforts.

Monday is World Tuberculosis (TB) Day, and a vaccine developed by the Gates Medical Research Institute is being studied in a phase 3 trial. If approved, the vaccine could potentially prevent pulmonary TB in adults and adolescents.

This week, recent studies include Mandimycin for resistant fungal infections, fluctuating hospital AMR rates, a 6-month HIV treatment, global challenges in hepatitis testing, and the start of a Lassa fever vaccine trial.